Glofitamab,Atezolizumab,Polatuzumab Vedotin,Obinutuzumab,Tocilizumab,89Zr-Df-IAB22M2C
Roche,Imaginab,JW Pharma
['pola', ' vedo', 'dlbcl', 'polatuzumab', 'lymsm', 'glofitamab']
congress|#17icml
martin hutchings( ), presents the updated data on glofitamab plus polatuzumab vedotin in r/r dlbcl which led to high &amp; durable responses &amp; a manageable safety profile. -best responses: orr of 78% &amp; cr: 56%
-mostly low-grade crs
#lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm